FOLR2 and neoplasm: Specifically targeting FRβ with chimeric antigen receptor (CAR)-T resulted in the elimination of FRβ+ TAMs, an enrichment of pro-inflammatory monocytes, an influx of cytotoxic CD8+ T cells, the inhibition of tumor progression, and better prognosis in a mouse model [190].